Initial experiments were performed for evaluation of growth inhibition by the new compounds against six human breast cancer cell lines, including MCF-7 (ER+/PR+, HER-2-), BT474 (ER+/PR+, HER-2+), SKBR-3 (ER-/PR-/HER-2+), MDA-MB-436 (ER-/PR-/HER-2-), MDA-MB-231 (ER-/PR-/HER-2-), MDA-MB-468 (ER-/PR-/HER-2-) and non-tumorigenic MCF-10A cells. Here, ERBB2 is linked to breast carcinoma.